Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias

類似資料

• New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study
  著者:: Taher, Ali T., 等
  出版事項: (2017)
• Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
  著者:: Tartaglione, Immacolata, 等
  出版事項: (2020)
• Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis
  著者:: Taher, Ali T., 等
  出版事項: (2019)
• Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
  著者:: Taher, Ali T, 等
  出版事項: (2014)
• Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
  著者:: Aydinok, Yesim, 等
  出版事項: (2015)